查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1492596

巨细胞病毒治疗市场：按疾病、药物、分销管道、应用分类 - 全球预测 2024-2030

Cytomegalovirus Treatment Market by Diseases (Encephalitis, Gastrointestinal Ulcers, Pneumonia), Drug (Cidofovir, Foscarnet, Ganciclovir), Distribution Channel, Application - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

巨细胞病毒治疗市场规模预计2023年为5.3844亿美元，2024年达到5.7699亿美元，预计2030年将达到9.0339亿美元，复合年增长率为7.67%。

巨细胞病毒(CMV) 治疗包括管理和治疗巨细胞病毒感染的整体医疗程序。巨细胞病毒是一种常见病毒，属于疱疹组，常见于免疫力缺乏的患者和孕妇。治疗包括抗病毒药物和疫苗，如西多福韦、膦甲酸、更昔洛韦和缬更昔洛韦，主要用于医院和诊所。巨细胞病毒盛行率的不断增加以及对有效治疗和预防措施的需求正在推动对各种巨细胞病毒（CMV）治疗的需求。此外，随着爱滋病毒/爱滋病、癌症治疗和器官移植等疾病导致免疫力缺乏的患者数量不断增加，对强大的 CMV 管理解决方案的需求也迅速增加。然而，对鉅细胞病毒株的抗药性以及与先进治疗相关的高成本是低收入地区鉅细胞病毒治疗面临的挑战。与先进治疗相关的高成本和 CMV 挖掘阻力问题阻碍了市场成长。此外，对 CMV 普遍缺乏认识阻碍了 CMV 相关疾病的早期诊断和开始治疗。监管环境也是一个挑战，严格的医药品认证过程可能会减缓新治疗方法的推出。然而，由于改善药物传递的奈米技术、个人化医疗的基因研究以及汇集资源和专业知识以增强治疗解决方案的合作研究等创新，该市场具有广阔的成长潜力。

主要市场统计
基准年[2023] 53844万美元
预测年份 [2024] 57699万美元
预测年份 [2030] 90339万美元
复合年增长率（%） 7.67%

区域洞察

在美国，先进的研究、全面的健康保险和活跃的新疗法市场正在推动 CMV 治疗。加拿大政府资助的医疗保健系统确保持续获得​​ CMV 治疗，这是市场成长的动力。在南美洲，提高意识和有针对性的教育计划，特别是有关先天性鉅细胞病毒的教育计划，正在支持市场成长，从而改善早期诊断并扩大治疗覆盖范围。在亚太地区，中国的医疗改革促进了获得治疗的机会，日本透过完善的医疗保险体系提供了广泛的覆盖面，而印度儘管基础设施存在差距，但改善了获得治疗的机会，特别是在都市区进展迅速。同时，东南亚国家正在透过推动研究和采用新的临床设施和 CMV 疗法来增加其全球临床影响力。在欧洲、中东和非洲，欧盟国家正在大力投资鉅细胞病毒治疗的研究和进展。在中东国家，特别是阿拉伯联合大公国和沙乌地阿拉伯，随着大众对鉅细胞病毒治疗的认识不断提高，医疗设施迅速发展，治疗可能性不断扩大。在非洲，新的 CMV 治疗方法正在透过国际援助和发展计划得到采用，重点是改善整体健康状况，以支持市场成长。

FPNV定位矩阵

FPNV 定位矩阵对于评估供应商在巨细胞病毒治疗市场的定位至关重要。此矩阵提供了对供应商的全面评估，并检查了与商务策略和产品满意度相关的关键指标。这种详细的评估使用户能够根据自己的要求做出明智的决定。根据评估结果，供应商被分为代表其成功程度的四个像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市场占有率分析

市场占有率分析是一种综合工具，可以对巨细胞病毒治疗市场供应商的现状进行深入而详细的评估。透过仔细比较和分析供应商的贡献，您可以更深入地了解每个供应商的绩效以及他们在争夺市场占有率时面临的挑战。这些贡献包括整体收益、客户群和其他关键指标。此外，该分析还提供了对该行业竞争力的宝贵见解，包括在研究基准年期间观察到的累积、分散主导地位和合併特征等因素。有了这些详细信息，供应商可以做出更明智的决策并製定有效的策略，以在市场竞争中保持领先地位。

策略分析与建议

策略分析对于寻求在全球市场站稳脚跟的组织至关重要。对巨细胞病毒治疗市场当前地位的全面评估使公司能够做出符合其长期愿望的明智决策。此关键评估涉及对组织的资源、能力和整体绩效进行彻底分析，以确定核心优势和需要改进的领域。

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 巨细胞病毒感染的传播
      • 提高对 CMV 及其影响的认识以及不断上涨的医疗费用
    • 抑制因素
      • 治疗成本高且商业化受到限制
    • 机会
      • CMV诊疗技术进展
      • 增加对医疗基础设施的投资，以改善获得先进 CMV 治疗的机会
    • 任务
      • CMV 治疗开发中的监管和标准化挑战
  • 市场区隔分析
    • 药物：更昔洛韦的使用增加，这是治疗巨细胞病毒的主要药物
    • 分销管道：透过提供个人化指导和频繁给药，扩大医院药房获得 CMV 治疗的机会
  • 市场扰动分析
  • 波特五力分析
  • 价值炼和关键路径分析
  • 价格分析
  • 技术分析
  • 专利分析
  • 贸易分析
  • 法规结构分析

第六章巨细胞病毒治疗市场：依疾病分类

  • 脑炎
  • 胃肠道溃疡
  • 肺炎
  • 视网膜炎

第七章巨细胞病毒治疗市场：依药物分类

  • 西多福韦
  • 膦甲酸
  • 更昔洛韦
  • 缬更昔洛韦

第八章巨细胞病毒治疗市场：按分销管道

  • 医院药房
  • 网路药房
  • 零售药房

第九章巨细胞病毒治疗市场：依应用分类

  • 先天性鉅细胞病毒感染疾病
  • 器官移植
  • 干细胞移植

第10章美洲巨细胞病毒治疗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太地区巨细胞病毒治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲的巨细胞病毒治疗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • 移植后巨细胞病毒感染新疗法「Livtencity」在中国核准
    • 默克公司的 PREVYMIS 获得 CHMP核准，用于在肾臟和干细胞移植患者中扩大 CMV 预防
    • 美国市售的 Kamata CYTOGAM 功能增强和肺移植中 CMV 预防的显着临床资料
  • 战略分析和建议

第14章竞争产品组合

  • 主要企业简介
  • 主要产品系列
Product Code: MRR-7949F05839D1

[196 Pages Report] The Cytomegalovirus Treatment Market size was estimated at USD 538.44 million in 2023 and expected to reach USD 576.99 million in 2024, at a CAGR 7.67% to reach USD 903.39 million by 2030.

The cytomegalovirus (CMV) treatment includes all aspects of medical practices to manage and treat cytomegalovirus infections, a common virus in the herpes group, found predominantly in immunocompromised individuals and pregnant women. The treatment includes antiviral drugs and vaccines such as cidofovir, foscarnet, ganciclovir & valganciclovir, which hospitals & clinics predominately utilize. The increased prevalence of cytomegalovirus and the acute need for its effective treatment and preventive measures drive the need for various cytomegalovirus (CMV) treatments. Moreover, with the rising number of immunocompromised patients owing to conditions such as HIV/AIDS, cancer therapies, and organ transplants, there is a burgeoning need for robust CMV management solutions. However, dug-resistant to CMV strains and the high cost associated with advanced treatment are the challenges faced by CMV treatments in low-income regions. High costs associated with advanced treatment and dug-resistant issues with CMV hamper the market growth. Additionally, a general lack of awareness about CMV hinders early diagnosis and treatment initiation for CMV-related diseases. The regulatory landscape also presents challenges, with stringent drug approval processes potentially slowing the introduction of new therapies. However, the market holds promising potential for growth through innovations such as nanotechnology for improved drug delivery, genetic research for personalized medicine, and collaborative efforts that pool resources and expertise for enhanced treatment solutions.

KEY MARKET STATISTICS
Base Year [2023] USD 538.44 million
Estimated Year [2024] USD 576.99 million
Forecast Year [2030] USD 903.39 million
CAGR (%) 7.67%

Regional Insights

In the Americas, the United States is involved in advanced research, comprehensive health insurance, and a proactive market for new treatments, which drive CMV treatment. Canada's government-funded healthcare system ensures consistent access to CMV therapies, which drives market growth. In South America, raising awareness and targeted educational programs, particularly concerning congenital CMV, are improving early diagnosis and expanding treatment coverage to support market growth. In the Asia Pacific region, China's healthcare reforms have boosted treatment access, Japan offers extensive coverage through a refined health insurance system, and India, despite its infrastructural discrepancies, is quickly advancing in treatment availability, particularly in urban centers. Meanwhile, Southeast Asian countries are enhancing their global clinical presence by advancing research and adopting new clinical facilities and medication for CMV treatments. In Europe, the Middle East, and Africa, the EU countries have invested considerably in research and the advancement of CMV treatment. In the Middle East, countries, particularly the UAE and Saudi Arabia, are rapidly developing medical facilities and expanding treatment availability, paralleled by growing public awareness related to CMV treatments. In Africa, the adoption of newer CMV treatments through international aid and developmental programs focusing on improving overall health outcomes supports market growth.

Market Insights

  • Market Dynamics

The market dynamics represent an ever-changing landscape of the Cytomegalovirus Treatment Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

    • Market Drivers
      • Increasing prevalence of cytomegalovirus infections
      • Increasing awareness about CMV and its implications, coupled with rising healthcare spending
    • Market Restraints
      • High cost of treatment coupled with limited commercialization
    • Market Opportunities
      • Advancements in CMV diagnosis and treatment technologies
      • Growing investment in healthcare infrastructure to increase the accessibility of advanced CMV treatments
    • Market Challenges
      • Regulatory and standardization challenges in CMV treatment development
  • Market Segmentation Analysis
    • Drug: Growing usage of ganciclovir primary medication to treat cytomegalovirus
    • Distribution Channel: Growing accessibility of CMV treatments across Hospital pharmacies as it provides personal guidance and frequent medication
  • Market Disruption Analysis
  • Porter's Five Forces Analysis
  • Value Chain & Critical Path Analysis
  • Pricing Analysis
  • Technology Analysis
  • Patent Analysis
  • Trade Analysis
  • Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Cytomegalovirus Treatment Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Cytomegalovirus Treatment Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

Approval of LIVTENCITY in China a Novel Treatment for Post-Transplant Cytomegalovirus Infections

Takeda Pharmaceutical announced that China's National Medical Products Administration has granted approval for LIVTENCITY (maribavir) to treat adult patients who have had either hematopoietic stem cell or solid organ transplants and are facing cytomegalovirus (CMV) infections that have shown resistance to conventional treatments. The approval was influenced by the Phase 3 SOLSTICE trial results, illustrating that LIVTENCITY is more effective than traditional antiviral therapies in achieving CMV viremia clearance eight weeks post-treatment. This marks the twelfth global approval of LIVTENCITY, reinforcing its therapeutic significance and international acceptance in handling challenging post-transplant CMV cases. [Published On: 2023-12-21]

Merck's PREVYMIS Gains CHMP Endorsement for Extended CMV Prophylaxis in Kidney and Stem Cell Transplant Recipients

Merck has received a favorable opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). This recommendation endorses the use of PREVYMIS (letermovir) to prevent cytomegalovirus (CMV) disease in high-risk adult transplant recipient groups. PREVYMIS has demonstrated effectiveness in clinical trials, specifically in a Phase 3 trial with 589 adult kidney transplant recipients and a placebo-controlled study focused on extended dosing for HSCT patients. [Published On: 2023-10-17]

Kamada's CYTOGAM Enhancements in U.S. Commercial Availability and Notable Clinical Data on CMV Prophylaxis in Lung Transplants

Kamada Ltd. has achieved USFDA approval for CYTOGAM to prevent cytomegalovirus (CMV) disease among various organ transplant recipients. Following a successful FDA-approved transfer of its manufacturing process to Kamada's facility in Beit Kama, Israel, the product is now available for U.S. commercial sale, with expectations to reach the Canadian market by year-end. Additionally, groundbreaking clinical data was unveiled at IDWeek 2023 in Boston, showcasing a five-year retrospective study by Dr. Fernando Torres at the University of Texas Southwestern Medical Center. [Published On: 2023-10-16]

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Cytomegalovirus Treatment Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Cytomegalovirus Treatment Market, highlighting leading vendors and their innovative profiles. These include Aetos Pharma Private Limited, Ajanta Pharma Ltd., Cipla Limited, Emcure Pharmaceuticals Limited, Exela Pharma Sciences, LLC, F. Hoffmann-La Roche Ltd, Fresenius Kabi AG, GlaxoSmithKline PLC, LEXICARE PHARMA PVT. LTD., Merck & Co., Inc, Rakshit Pharmaceuticals Limited, Teva Pharmaceutical Industries Ltd., Weefsel Pharma, and Xediton Pharmaceuticals Inc..

Market Segmentation & Coverage

This research report categorizes the Cytomegalovirus Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Diseases
    • Encephalitis
    • Gastrointestinal Ulcers
    • Pneumonia
    • Retinitis
  • Drug
    • Cidofovir
    • Foscarnet
    • Ganciclovir
    • Valganciclovir
  • Distribution Channel
    • Hospital Pharmacy
    • Online Pharmacy
    • Retail Pharmacy
  • Application
    • Congenital CMV Infection
    • Organ Transplantation
    • Stem Cell Transplantation
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of cytomegalovirus infections
      • 5.1.1.2. Increasing awareness about CMV and its implications, coupled with rising healthcare spending
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of treatment coupled with limited commercialization
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in CMV diagnosis and treatment technologies
      • 5.1.3.2. Growing investment in healthcare infrastructure to increase the accessibility of advanced CMV treatments
    • 5.1.4. Challenges
      • 5.1.4.1. Regulatory and standardization challenges in CMV treatment development
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Drug: Growing usage of ganciclovir primary medication to treat cytomegalovirus
    • 5.2.2. Distribution Channel: Growing accessibility of CMV treatments across Hospital pharmacies as it provides personal guidance and frequent medication
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Cytomegalovirus Treatment Market, by Diseases

  • 6.1. Introduction
  • 6.2. Encephalitis
  • 6.3. Gastrointestinal Ulcers
  • 6.4. Pneumonia
  • 6.5. Retinitis

7. Cytomegalovirus Treatment Market, by Drug

  • 7.1. Introduction
  • 7.2. Cidofovir
  • 7.3. Foscarnet
  • 7.4. Ganciclovir
  • 7.5. Valganciclovir

8. Cytomegalovirus Treatment Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Hospital Pharmacy
  • 8.3. Online Pharmacy
  • 8.4. Retail Pharmacy

9. Cytomegalovirus Treatment Market, by Application

  • 9.1. Introduction
  • 9.2. Congenital CMV Infection
  • 9.3. Organ Transplantation
  • 9.4. Stem Cell Transplantation

10. Americas Cytomegalovirus Treatment Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Cytomegalovirus Treatment Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Cytomegalovirus Treatment Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Approval of LIVTENCITY in China a Novel Treatment for Post-Transplant Cytomegalovirus Infections
    • 13.3.2. Merck's PREVYMIS Gains CHMP Endorsement for Extended CMV Prophylaxis in Kidney and Stem Cell Transplant Recipients
    • 13.3.3. Kamada's CYTOGAM Enhancements in U.S. Commercial Availability and Notable Clinical Data on CMV Prophylaxis in Lung Transplants
  • 13.4. Strategy Analysis & Recommendation

14. Competitive Portfolio

  • 14.1. Key Company Profiles
  • 14.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. CYTOMEGALOVIRUS TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. CYTOMEGALOVIRUS TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. CYTOMEGALOVIRUS TREATMENT MARKET DYNAMICS
  • FIGURE 7. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. AMERICAS CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 18. UNITED STATES CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. ASIA-PACIFIC CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. ASIA-PACIFIC CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. CYTOMEGALOVIRUS TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 24. CYTOMEGALOVIRUS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CYTOMEGALOVIRUS TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY ENCEPHALITIS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY ENCEPHALITIS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY GASTROINTESTINAL ULCERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY GASTROINTESTINAL ULCERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY PNEUMONIA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY PNEUMONIA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY RETINITIS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY RETINITIS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY CIDOFOVIR, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY CIDOFOVIR, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY FOSCARNET, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY FOSCARNET, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY GANCICLOVIR, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY GANCICLOVIR, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY VALGANCICLOVIR, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY VALGANCICLOVIR, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY CONGENITAL CMV INFECTION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY CONGENITAL CMV INFECTION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY ORGAN TRANSPLANTATION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY ORGAN TRANSPLANTATION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY STEM CELL TRANSPLANTATION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY STEM CELL TRANSPLANTATION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 43. AMERICAS CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2023 (USD MILLION)
  • TABLE 44. AMERICAS CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2024-2030 (USD MILLION)
  • TABLE 45. AMERICAS CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 46. AMERICAS CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 47. AMERICAS CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 48. AMERICAS CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 49. AMERICAS CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 50. AMERICAS CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 51. AMERICAS CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 52. AMERICAS CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 53. ARGENTINA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2023 (USD MILLION)
  • TABLE 54. ARGENTINA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2024-2030 (USD MILLION)
  • TABLE 55. ARGENTINA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 56. ARGENTINA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 57. ARGENTINA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 58. ARGENTINA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 59. ARGENTINA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 60. ARGENTINA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 61. BRAZIL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2023 (USD MILLION)
  • TABLE 62. BRAZIL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2024-2030 (USD MILLION)
  • TABLE 63. BRAZIL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 64. BRAZIL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 65. BRAZIL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 66. BRAZIL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 67. BRAZIL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 68. BRAZIL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 69. CANADA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2023 (USD MILLION)
  • TABLE 70. CANADA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2024-2030 (USD MILLION)
  • TABLE 71. CANADA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 72. CANADA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 73. CANADA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 74. CANADA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 75. CANADA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 76. CANADA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 77. MEXICO CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2023 (USD MILLION)
  • TABLE 78. MEXICO CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2024-2030 (USD MILLION)
  • TABLE 79. MEXICO CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 80. MEXICO CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 81. MEXICO CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 82. MEXICO CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 83. MEXICO CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 84. MEXICO CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 85. UNITED STATES CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2023 (USD MILLION)
  • TABLE 86. UNITED STATES CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2024-2030 (USD MILLION)
  • TABLE 87. UNITED STATES CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 88. UNITED STATES CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 89. UNITED STATES CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 90. UNITED STATES CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 91. UNITED STATES CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 92. UNITED STATES CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 93. UNITED STATES CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 94. UNITED STATES CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2023 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2024-2030 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 105. AUSTRALIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2023 (USD MILLION)
  • TABLE 106. AUSTRALIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2024-2030 (USD MILLION)
  • TABLE 107. AUSTRALIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 108. AUSTRALIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 109. AUSTRALIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 110. AUSTRALIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 111. AUSTRALIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 112. AUSTRALIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 113. CHINA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2023 (USD MILLION)
  • TABLE 114. CHINA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2024-2030 (USD MILLION)
  • TABLE 115. CHINA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 116. CHINA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 117. CHINA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 118. CHINA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 119. CHINA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 120. CHINA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 121. INDIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2023 (USD MILLION)
  • TABLE 122. INDIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2024-2030 (USD MILLION)
  • TABLE 123. INDIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 124. INDIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 125. INDIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 126. INDIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 127. INDIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 128. INDIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 129. INDONESIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2023 (USD MILLION)
  • TABLE 130. INDONESIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2024-2030 (USD MILLION)
  • TABLE 131. INDONESIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 132. INDONESIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 133. INDONESIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 134. INDONESIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 135. INDONESIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 136. INDONESIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 137. JAPAN CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2023 (USD MILLION)
  • TABLE 138. JAPAN CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2024-2030 (USD MILLION)
  • TABLE 139. JAPAN CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 140. JAPAN CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 141. JAPAN CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 142. JAPAN CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 143. JAPAN CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 144. JAPAN CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 145. MALAYSIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2023 (USD MILLION)
  • TABLE 146. MALAYSIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2024-2030 (USD MILLION)
  • TABLE 147. MALAYSIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 148. MALAYSIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 149. MALAYSIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 150. MALAYSIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 151. MALAYSIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 152. MALAYSIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 153. PHILIPPINES CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2023 (USD MILLION)
  • TABLE 154. PHILIPPINES CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2024-2030 (USD MILLION)
  • TABLE 155. PHILIPPINES CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 156. PHILIPPINES CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 157. PHILIPPINES CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 158. PHILIPPINES CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 159. PHILIPPINES CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 160. PHILIPPINES CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 161. SINGAPORE CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2023 (USD MILLION)
  • TABLE 162. SINGAPORE CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2024-2030 (USD MILLION)
  • TABLE 163. SINGAPORE CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 164. SINGAPORE CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 165. SINGAPORE CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 166. SINGAPORE CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 167. SINGAPORE CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 168. SINGAPORE CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 169. SOUTH KOREA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2023 (USD MILLION)
  • TABLE 170. SOUTH KOREA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2024-2030 (USD MILLION)
  • TABLE 171. SOUTH KOREA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 172. SOUTH KOREA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 173. SOUTH KOREA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 174. SOUTH KOREA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 175. SOUTH KOREA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 176. SOUTH KOREA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 177. TAIWAN CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2023 (USD MILLION)
  • TABLE 178. TAIWAN CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2024-2030 (USD MILLION)
  • TABLE 179. TAIWAN CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 180. TAIWAN CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 181. TAIWAN CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 182. TAIWAN CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 183. TAIWAN CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 184. TAIWAN CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 185. THAILAND CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2023 (USD MILLION)
  • TABLE 186. THAILAND CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2024-2030 (USD MILLION)
  • TABLE 187. THAILAND CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 188. THAILAND CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 189. THAILAND CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 190. THAILAND CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 191. THAILAND CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 192. THAILAND CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 193. VIETNAM CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2023 (USD MILLION)
  • TABLE 194. VIETNAM CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2024-2030 (USD MILLION)
  • TABLE 195. VIETNAM CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 196. VIETNAM CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 197. VIETNAM CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 198. VIETNAM CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 199. VIETNAM CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 200. VIETNAM CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2023 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2024-2030 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 211. DENMARK CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2023 (USD MILLION)
  • TABLE 212. DENMARK CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2024-2030 (USD MILLION)
  • TABLE 213. DENMARK CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 214. DENMARK CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 215. DENMARK CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 216. DENMARK CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 217. DENMARK CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 218. DENMARK CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 219. EGYPT CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2023 (USD MILLION)
  • TABLE 220. EGYPT CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2024-2030 (USD MILLION)
  • TABLE 221. EGYPT CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 222. EGYPT CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 223. EGYPT CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 224. EGYPT CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 225. EGYPT CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 226. EGYPT CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 227. FINLAND CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2023 (USD MILLION)
  • TABLE 228. FINLAND CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2024-2030 (USD MILLION)
  • TABLE 229. FINLAND CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 230. FINLAND CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 231. FINLAND CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 232. FINLAND CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 233. FINLAND CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 234. FINLAND CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 235. FRANCE CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2023 (USD MILLION)
  • TABLE 236. FRANCE CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2024-2030 (USD MILLION)
  • TABLE 237. FRANCE CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 238. FRANCE CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 239. FRANCE CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 240. FRANCE CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 241. FRANCE CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 242. FRANCE CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 243. GERMANY CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2023 (USD MILLION)
  • TABLE 244. GERMANY CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2024-2030 (USD MILLION)
  • TABLE 245. GERMANY CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 246. GERMANY CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 247. GERMANY CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 248. GERMANY CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 249. GERMANY CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 250. GERMANY CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 251. ISRAEL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2023 (USD MILLION)
  • TABLE 252. ISRAEL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2024-2030 (USD MILLION)
  • TABLE 253. ISRAEL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 254. ISRAEL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 255. ISRAEL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 256. ISRAEL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 257. ISRAEL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 258. ISRAEL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 259. ITALY CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2023 (USD MILLION)
  • TABLE 260. ITALY CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2024-2030 (USD MILLION)
  • TABLE 261. ITALY CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 262. ITALY CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 263. ITALY CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 264. ITALY CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 265. ITALY CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 266. ITALY CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 267. NETHERLANDS CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2023 (USD MILLION)
  • TABLE 268. NETHERLANDS CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2024-2030 (USD MILLION)
  • TABLE 269. NETHERLANDS CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 270. NETHERLANDS CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 271. NETHERLANDS CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 272. NETHERLANDS CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 273. NETHERLANDS CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 274. NETHERLANDS CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 275. NIGERIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2023 (USD MILLION)
  • TABLE 276. NIGERIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2024-2030 (USD MILLION)
  • TABLE 277. NIGERIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 278. NIGERIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 279. NIGERIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 280. NIGERIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 281. NIGERIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 282. NIGERIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 283. NORWAY CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2023 (USD MILLION)
  • TABLE 284. NORWAY CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2024-2030 (USD MILLION)
  • TABLE 285. NORWAY CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 286. NORWAY CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 287. NORWAY CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 288. NORWAY CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 289. NORWAY CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 290. NORWAY CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 291. POLAND CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2023 (USD MILLION)
  • TABLE 292. POLAND CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2024-2030 (USD MILLION)
  • TABLE 293. POLAND CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 294. POLAND CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 295. POLAND CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 296. POLAND CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 297. POLAND CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 298. POLAND CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 299. QATAR CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2023 (USD MILLION)
  • TABLE 300. QATAR CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2024-2030 (USD MILLION)
  • TABLE 301. QATAR CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 302. QATAR CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 303. QATAR CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 304. QATAR CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 305. QATAR CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 306. QATAR CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 307. RUSSIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2023 (USD MILLION)
  • TABLE 308. RUSSIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2024-2030 (USD MILLION)
  • TABLE 309. RUSSIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 310. RUSSIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 311. RUSSIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 312. RUSSIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 313. RUSSIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 314. RUSSIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 315. SAUDI ARABIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2023 (USD MILLION)
  • TABLE 316. SAUDI ARABIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2024-2030 (USD MILLION)
  • TABLE 317. SAUDI ARABIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 318. SAUDI ARABIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 319. SAUDI ARABIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 320. SAUDI ARABIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 321. SAUDI ARABIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 322. SAUDI ARABIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 323. SOUTH AFRICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2023 (USD MILLION)
  • TABLE 324. SOUTH AFRICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2024-2030 (USD MILLION)
  • TABLE 325. SOUTH AFRICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 326. SOUTH AFRICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 327. SOUTH AFRICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 328. SOUTH AFRICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 329. SOUTH AFRICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 330. SOUTH AFRICA CYTOMEGALOVIRUS TREATMENT MAR